Navigation Links
Fuse Science Announces the Launch of its Analgesic and Diabetic Oral Fuse Delivery (OFD) Research Project Platforms
Date:12/20/2011

AVENTURA, Fla., Dec. 20, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd. (OTCQB: DROP), the parent company of Fuse Science, Inc. (www.fusescience.com), announced today the formal launch of its Hypoglycemic, Hyperglycemic, and  Analgesic project platforms for the advancement of its OTC and pharmaceutical licensing efforts.  

Some of the proprietary science platforms that Fuse Science deals with are oral fuse delivery technologies (OFD's). These OFD's are placed under the tongue or in the inner cheek of the patient where they are absorbed and release the applicable active or nutrient into the blood stream.  OFD's do not require water and may be more convenient to take than liquids or injections.  OFD's are especially designed to be very useful with pediatric and geriatric patients or anyone in need of faster absorption of a given active into the blood stream that bypasses the GI track, providing an alternative to the more traditional invasive drug delivery systems.

"Today we announce the further advancement of the true core of our Powered by Fuse™ technology," said Brian Tuffin, Fuse Science Chief Executive Officer. "It is with high confidence that we advance our OFD Analgesic, Hypoglycemic and Hyperglycemic project platforms with the objective of completing our pediatric and adult formulations to provide an effective sublingual and/or Buccal delivery alternative for the respective drugs."

The business opportunities from these project platforms are as follows:

  • The side effects of aspirin on the stomach include bleeding of the abdomen and deterioration of the stomach lining.  By bypassing the GI track with our drop technology we intend to improve performance and usage in the $2.5 billion adult analgesic category.
  • The largest disease state globally is diabetes with an estimated 285 million people, corresponding to 6.4% of the world's adult population living with diabetes in 2010. The number is expected to grow to 438 million by 2030, or 7.8% of the adult population. . One major issue associated with the treatment of diabetes is lack of compliance. The ease of use associated with the OFD will help address the major compliance issues in this $25 billion dollar treatment category worldwide.

"We are extremely passionate about our work in this area," said Ed Maliski, Ph.D. & Lead scientist. "Our work is born out of diabetes sufferers on staff who are committed to advancing these platforms with sense of urgency. We have produced significant results with our OFD work and feel very confident at this stage with our ability to advance these project platforms."

"We continue to be very deliberate and focused with every step we take as a company and our efforts in the OTC and Pharmaceutical space represents the foundation to our long term focus," added Tuffin.  "These actions in combination with the with the long awaited, Powered by Fuse™ EnerJel™ launch on December 30th, 2011 at www.poweredbyfuse.com are calculated steps in our effort to create long term shareholder value."

About Double Eagle Holdings
Double Eagle Holdings (OTCQB: DROP) is the parent company of Fuse Science, Inc., an innovative consumer products holding company based in Aventura, Florida.  The corporate name, Double Eagle Holdings is in the process of being changed to Fuse Science Inc.  Fuse Science is the developer of new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.  The company has successfully developed and maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly – all in a concentrated "DROP" form that is simply applied under the tongue.  The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products.  Information about Fuse Science is available online at www.fusescience.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.



'/>"/>
SOURCE Double Eagle Holdings
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
8. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... While it’s often ... a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She ... in darkness or restricted lighting. As such, it eliminates the need to turn on ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):